X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs LUPIN - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA LUPIN GLENMARK PHARMA/
LUPIN
 
P/E (TTM) x 13.4 40.9 32.7% View Chart
P/BV x 2.4 2.5 95.6% View Chart
Dividend Yield % 0.4 0.7 66.1%  

Financials

 GLENMARK PHARMA   LUPIN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
LUPIN
Mar-18
GLENMARK PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs9301,465 63.5%   
Low Rs517727 71.2%   
Sales per share (Unadj.) Rs322.6349.6 92.3%  
Earnings per share (Unadj.) Rs28.55.6 512.6%  
Cash flow per share (Unadj.) Rs39.229.6 132.5%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.30.5 60.6%  
Book value per share (Unadj.) Rs183.0300.3 60.9%  
Shares outstanding (eoy) m282.17452.08 62.4%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x2.23.1 71.5%   
Avg P/E ratio x25.4197.2 12.9%  
P/CF ratio (eoy) x18.537.1 49.8%  
Price / Book Value ratio x4.03.6 108.4%  
Dividend payout %7.090.0 7.8%   
Avg Mkt Cap Rs m204,206495,502 41.2%   
No. of employees `00013.717.0 80.5%   
Total wages/salary Rs m18,71828,647 65.3%   
Avg. sales/employee Rs Th6,636.89,273.6 71.6%   
Avg. wages/employee Rs Th1,364.71,681.0 81.2%   
Avg. net profit/employee Rs Th586.1147.4 397.5%   
INCOME DATA
Net Sales Rs m91,031158,042 57.6%  
Other income Rs m9141,504 60.8%   
Total revenues Rs m91,945159,545 57.6%   
Gross profit Rs m16,15431,475 51.3%  
Depreciation Rs m3,01910,859 27.8%   
Interest Rs m2,8562,044 139.7%   
Profit before tax Rs m11,19320,076 55.8%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m3,1552,885 109.4%   
Profit after tax Rs m8,0392,513 319.9%  
Gross profit margin %17.719.9 89.1%  
Effective tax rate %28.214.4 196.1%   
Net profit margin %8.81.6 555.5%  
BALANCE SHEET DATA
Current assets Rs m69,887122,095 57.2%   
Current liabilities Rs m32,87950,956 64.5%   
Net working cap to sales %40.745.0 90.3%  
Current ratio x2.12.4 88.7%  
Inventory Days Days8185 96.3%  
Debtors Days Days93120 78.0%  
Net fixed assets Rs m28,892129,876 22.2%   
Share capital Rs m282904 31.2%   
"Free" reserves Rs m51,353134,866 38.1%   
Net worth Rs m51,635135,771 38.0%   
Long term debt Rs m41,41864,245 64.5%   
Total assets Rs m125,954263,054 47.9%  
Interest coverage x4.910.8 45.4%   
Debt to equity ratio x0.80.5 169.5%  
Sales to assets ratio x0.70.6 120.3%   
Return on assets %8.61.7 499.4%  
Return on equity %15.61.9 841.3%  
Return on capital %15.13.7 405.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31753,141 68.3%   
Fx outflow Rs m9,72019,335 50.3%   
Net fx Rs m26,59833,807 78.7%   
CASH FLOW
From Operations Rs m16,48117,512 94.1%  
From Investments Rs m-10,133-14,073 72.0%  
From Financial Activity Rs m-4,685-14,921 31.4%  
Net Cashflow Rs m1,770-11,482 -15.4%  

Share Holding

Indian Promoters % 48.3 46.6 103.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 6.9 11.3 61.1%  
FIIs % 34.4 31.9 107.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.1 104.0%  
Shareholders   56,727 98,259 57.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ORCHID PHARMA LTD  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Over 300 Points Higher; Energy and Metal Stocks Witness Buying(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

This Little-Known Opportunity Promises Both Health and Wealth for Your Grandchildren(Profit Hunter)

Jun 20, 2019

The next big opportunity that has the potential to make you both rich and healthy.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 25, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - MERCK COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS